NCT07168876 Colon Cancer Liquid Biopsy Investigation of Methylation-based Biomarkers Evaluation Using Delta-HLD (CLIMBED)
| NCT ID | NCT07168876 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Epiliquid Holding, Inc |
| Condition | Colorectal Cancer (CRC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,200 participants |
| Start Date | 2024-04-04 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,200 participants in total. It began in 2024-04-04 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
CLIMBED (Colon cancer Liquid biopsy Investigation of Methylation-based Biomarkers Evaluation using Delta-HLD) is a non-randomized, observational, cross-sectional clinical validation study designed to assess the performance of Delta-HLD, Epiliquid's proprietary liquid biopsy technology, for colorectal cancer (CRC) detection. The study will evaluate the test performance in an average-risk population for CRC undergoing screening colonoscopy, which will serve as the gold standard reference.
Eligibility Criteria
Inclusion Criteria: * Men and women aged 45-75 years * Indication of colorectal cancer screening colonoscopy by treating physician Exclusion Criteria: * First-degree family history of CRC * Inflammatory bowel disease (ulcerative colitis, Crohn's disease) * Other malignancies within 5 years * Known hereditary CRC syndromes (Lynch, FAP) * Major trauma, surgery, transfusion in past 30 days * Current participation in an interventional clinical trial
Contact & Investigator
Emanuel Campoy, PhD
STUDY DIRECTOR
CONICET-National Scientific and Technical Research Council
Frequently Asked Questions
Who can join the NCT07168876 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, up to 75 Years, studying Colorectal Cancer (CRC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07168876 currently recruiting?
Yes, NCT07168876 is actively recruiting participants. Contact the research team at victoria.bocanegra@epiliquid.com for enrollment information.
Where is the NCT07168876 trial being conducted?
This trial is being conducted at Mendoza, Argentina.
Who is sponsoring the NCT07168876 clinical trial?
NCT07168876 is sponsored by Epiliquid Holding, Inc. The principal investigator is Emanuel Campoy, PhD at CONICET-National Scientific and Technical Research Council. The trial plans to enroll 3,200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.